Heekyung Kim1, Ah Rum Baek2, Soyeon Kim2, Eun-Young Jeon3, MD. Kamrul Islam2, Garam Choi2, Bo Kyung Sung2, Tae-Jeong Kim3, and Yongmin Chang1,2,3,4
1BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu, Korea, Republic of, 2Medical &Biological Engineering, Kyungpook National University, 3Biomedical Engineering Research Instite, Kyungpook National University, 4Radiology, Kyungpook National University
Synopsis
Gd-EOB-DO3A is prepared according to the general
synthetic methods, and characterized by spectroscopic analysis. The
relaxivities are r1 =
8.07, r2 = 8.57 mM-1s-1.
From in vivo T1-weighted MR
images, we observe good liver-specific enhancement that can be compared with
commercial liver targeting agents, and confirm the biliary excretion via gallbladder.
Also the kinetic stability of the gadolinium complex was determined with time-dependent
longitudinal relaxation rate (R1,p(t)/R1,p(0)) and
the relaxation was maintained above 70% against to initial value during the
measurement.
Introduction
Magnetic Resonance
Imaging (MRI) has an important role in the detection of various liver diseases.
Several hepatobiliary MRI contrast agents (CAs) like Primovist©,
Multihance©, and Mn-DPDP (Teslacan©) have been
successfully used with good liver enhancement. However, Acyclic MRI CAs are
gadolinium complexes that have low kinetic stability causing various problems
in the human body like nephrogenic systemic fibrosis (NSF), deposition of
gadolinium ions in a brain.(1) On the other hand, it is well known
that macrocyclic MR CAs have higher kinetic stability than those of acyclic
types. In this study, we designed and synthesized a gadolinium based
macrocyclic MRI CA, Gd-DO3A-EOB for kinetically improved stability and liver
targeting property.Materials and Methods
All reagents were purchased
from commercial sources and used as received. Characterization of the
synthesized compounds have been determined by analytical spectroscopic methods.(2)
T1 measurements were
carried out using an inversion recovery method with variable inversion times (TI)
at1.5 T (64 MHz). For T2
measurements, the CPMG (Carr-Purcell-Meiboon-Gill) pulse sequence was adapted
for multiple spin-echo measurements. T1,
T2 relaxation times were
obtained from the nonlinear least-squares fit of the mean pixel values at
variable TI and TE, respectively. The relaxivities (r1 and r2)
were then calculated as a slope of linear fit of relaxation rate along with
concentrations. The in vivo MR
experiments was performed in accordance with the rules of the animal research
committee of Kyungpook National University (KNU). In these studies, the mice (26
~ 27 g) were anesthetized by 1.5% isoflurane in oxygen. MR images were acquired
before and after intravascular injection of each MR contrast agents
(Gd-DO3A-EOB, Primovist©, Multihance©; dose: 0.1 mmol Gd/kg). The images were acquired with a 1.5 T (GE
Healthcare, Milwaukee, WI, USA) equipped with a homemade small animal volume
coil. Also image parameters of coronal images for spin-echo are as follows:
Repetition time (TR) = 300 msec; echo time (TE) = 13 msec; 11 mm field of view
(FOV); 192 128 matrix size; 1.2 mm slice
thickness; number of acquisition (NEX) = 8; scan time of each image = 2 min 37
sec.(3) The kinetic inertness was measured by evaluating the time-dependent
longitudinal relaxation rate (R1,p(t)/R1,p(0)) of a buffered
solution (PBS, pH 7.4) containing 2.5 mmol/L gadolinium complex in presence of equimolar
ZnCl2. In vitro cell
toxicity of this compound was assessed with normal human kidney cell line
(HEK-293) at various concentrations.Result and Discussion
Scheme 1 shows the synthesis of
Gd-EOB-DO3A. Relaxivities of Gd-EOB-DO3A (r1 = 8.1, r2 =
8.6 mM-1s-1) are much higher than those of primovist©
(r1 = 4.7, r2 = 5.1 mM-1s-1) and
Multihance© (r1 = 4.0, r2 = 4.3 mM-1s-1).
Gd-EOB-DO3A shows high kinetic stability in chemically competitive environment,
retaining the longitudinal relaxation rate (R1,p(t)/R1,p(0)) above 70% , than
other acyclic liver targeting agents (Figure 1). In addition, Gd-DO3A-EOB does
not show particular cell toxicity with normal kidney cell, HEK-293 (Figure 2). In
vivo MRI experiment, Gd-DO3A-EOB
shows specifically good liver enhancement immediately after tail vein
injection. Also it is excreted via gallbladder, confirming hepatobiliary uptake
as seen in Figure 3. Figure 4 shows the axial T1-weighted MR images
of hepatocellular carcinoma (HCC) model nude mice which were obtained by tail
vein injection with Gd-EOB-DO3A and Gd-DOTA for comparative purpose. The
difference in Gd-EOB-DO3A uptake between normal hepatocytes and tumor cells
demonstrates significant difference in MR signal enhancement (Figure 4a). In
case of non-specific extracellular agent, Gd-DOTA, the MR images shows
undistinguishable contrast enhancement between normal liver tissue and tumor
regions. (Figure 4b). Therefore, Gd-EOB-DO3A demonstrated the significant
clinical potential to detect liver tumor and differentiate the margin between
normal liver cell and HCC.Conclusion
We have
synthesized Gd-DO3A-EOB as a highly stable liver targeting MRI CA.
The results shows that it might be useful as diagnostic agent in field of liver
disease with good hepatobiliary property and kinetic inertness. Therefore,
it can be concluded that in every respect, a new macrocyclic Gd-EOB-DO3A may
put an entry into a new family of practical liver-specific MRI CAs with more merits
than their linear counterparts.
Acknowledgements
No acknowledgement found.References
(1) Nevzat
Karabulut, Diagn. Interv. Radiol., 2015, 21, 269-270
(2) Nikolaos
Eleftheriadis, Frank J. Dekker, Eur. J.
Med. Chem., 2015, 94, 265-275
(3) Hee-Kyung Kim,
Tae-Joeng Kim, Youngmin Chang, J. Med.
Chem., 2013, 56, 8104-8111